Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.005 USD | +0.50% | -16.02% | -25.69% |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- Low profitability weakens the company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.69% | 7.4M | C- | ||
+9.30% | 46.03B | B | ||
+52.73% | 44.55B | A | ||
+7.15% | 40.8B | B- | ||
-8.78% | 28.25B | C | ||
+18.68% | 27.71B | B- | ||
-21.92% | 18.82B | B | ||
+14.62% | 13.91B | C+ | ||
+31.85% | 12.43B | C+ | ||
+4.47% | 10.81B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Eiger BioPharmaceuticals, Inc. - Nasdaq
- Ratings Eiger BioPharmaceuticals, Inc.